GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Piotroski F-Score

Hualan Biological Engineering (SZSE:002007) Piotroski F-Score : 5 (As of Apr. 16, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hualan Biological Engineering has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Hualan Biological Engineering's Piotroski F-Score or its related term are showing as below:

SZSE:002007' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Hualan Biological Engineering was 7. The lowest was 3. And the median was 6.


Hualan Biological Engineering Piotroski F-Score Historical Data

The historical data trend for Hualan Biological Engineering's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Piotroski F-Score Chart

Hualan Biological Engineering Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.00 4.00 6.00 5.00

Hualan Biological Engineering Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 6.00 5.00 5.00

Competitive Comparison of Hualan Biological Engineering's Piotroski F-Score

For the Biotechnology subindustry, Hualan Biological Engineering's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Engineering's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec24) TTM:Last Year (Dec23) TTM:
Net Income was 261.774 + 178.422 + 483.461 + 164.194 = ¥1,088 Mil.
Cash Flow from Operations was 50.186 + 271.15 + 138.373 + 599.636 = ¥1,059 Mil.
Revenue was 787.309 + 865.398 + 1837.941 + 888.548 = ¥4,379 Mil.
Gross Profit was 438.359 + 399.42 + 1318.444 + 534.733 = ¥2,691 Mil.
Average Total Assets from the begining of this year (Dec23)
to the end of this year (Dec24) was
(16105.783 + 16268.788 + 15637.537 + 16101.606 + 16309.951) / 5 = ¥16084.733 Mil.
Total Assets at the begining of this year (Dec23) was ¥16,106 Mil.
Long-Term Debt & Capital Lease Obligation was ¥9 Mil.
Total Current Assets was ¥9,616 Mil.
Total Current Liabilities was ¥2,360 Mil.
Net Income was 351.676 + 174.976 + 540.634 + 414.293 = ¥1,482 Mil.

Revenue was 880.663 + 704.579 + 2327.729 + 1428.902 = ¥5,342 Mil.
Gross Profit was 555.351 + 390.626 + 1778.89 + 992.527 = ¥3,717 Mil.
Average Total Assets from the begining of last year (Dec22)
to the end of last year (Dec23) was
(14743.379 + 15081.329 + 14492.807 + 15531.479 + 16105.783) / 5 = ¥15190.9554 Mil.
Total Assets at the begining of last year (Dec22) was ¥14,743 Mil.
Long-Term Debt & Capital Lease Obligation was ¥9 Mil.
Total Current Assets was ¥9,327 Mil.
Total Current Liabilities was ¥2,581 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hualan Biological Engineering's current Net Income (TTM) was 1,088. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Hualan Biological Engineering's current Cash Flow from Operations (TTM) was 1,059. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec23)
=1087.851/16105.783
=0.06754412

ROA (Last Year)=Net Income/Total Assets (Dec22)
=1481.579/14743.379
=0.10049114

Hualan Biological Engineering's return on assets of this year was 0.06754412. Hualan Biological Engineering's return on assets of last year was 0.10049114. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Hualan Biological Engineering's current Net Income (TTM) was 1,088. Hualan Biological Engineering's current Cash Flow from Operations (TTM) was 1,059. ==> 1,059 <= 1,088 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=8.777/16084.733
=0.00054567

Gearing (Last Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=9.148/15190.9554
=0.0006022

Hualan Biological Engineering's gearing of this year was 0.00054567. Hualan Biological Engineering's gearing of last year was 0.0006022. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec24)=Total Current Assets/Total Current Liabilities
=9616.191/2360.122
=4.07444658

Current Ratio (Last Year: Dec23)=Total Current Assets/Total Current Liabilities
=9326.542/2581.451
=3.61290685

Hualan Biological Engineering's current ratio of this year was 4.07444658. Hualan Biological Engineering's current ratio of last year was 3.61290685. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Hualan Biological Engineering's number of shares in issue this year was 1822.905. Hualan Biological Engineering's number of shares in issue last year was 1824.257. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=2690.956/4379.196
=0.61448631

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3717.394/5341.873
=0.69589711

Hualan Biological Engineering's gross margin of this year was 0.61448631. Hualan Biological Engineering's gross margin of last year was 0.69589711. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec23)
=4379.196/16105.783
=0.27190209

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec22)
=5341.873/14743.379
=0.36232352

Hualan Biological Engineering's asset turnover of this year was 0.27190209. Hualan Biological Engineering's asset turnover of last year was 0.36232352. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Hualan Biological Engineering has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Hualan Biological Engineering  (SZSE:002007) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Hualan Biological Engineering Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
Chen Zheng Yue Executives
Fan Bei Directors, executives
Pan Ruo Wen Executives
Xie Jun Min Directors, executives
An Wen Qi Executives
An Kang Directors, executives
Ma Xiao Wei Executives
Zhang Bao Xian Executives
An Wen Jue Director
Liu Jun Executives
Wang Qi Ping Directors, executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors

Hualan Biological Engineering Headlines

No Headlines